Evidence map›Paper›PMID 33842066›Full record

ArticleNeurology. Clinical practice2021

Prognosis Markers for Monitoring HTLV-1 Neurologic Disease.

Gabriela Prates, Tatiane Assone, Marcelo Corral, Maíra P M Baldassin, Tatiane Mitiko, Flávia C Silva Sales, Michel E Haziot, Jerusa Smid, Luiz A M Fonseca, Fernanda de Toledo Gonçalves and 2 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurology. Clinical practice, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Observational
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Gabriela PratesFaculty of Medicine-University of São Paulo (GP, TA, MC, MPMB, TM, FCSS, LAMF, JC); Institute of Infectious Diseases "Emilio Ribas" (MEH, JS, ACPdO); and Departamento de Medicina Legal, Ética Médica e Medicina Social e do Trabalho, Faculdade de Medicina FMUSP (FdTG), University of São Paulo, Brazil.
Tatiane AssoneFaculty of Medicine-University of São Paulo (GP, TA, MC, MPMB, TM, FCSS, LAMF, JC); Institute of Infectious Diseases "Emilio Ribas" (MEH, JS, ACPdO); and Departamento de Medicina Legal, Ética Médica e Medicina Social e do Trabalho, Faculdade de Medicina FMUSP (FdTG), University of São Paulo, Brazil.ORCID 0000-0003-0993-4523
Marcelo CorralFaculty of Medicine-University of São Paulo (GP, TA, MC, MPMB, TM, FCSS, LAMF, JC); Institute of Infectious Diseases "Emilio Ribas" (MEH, JS, ACPdO); and Departamento de Medicina Legal, Ética Médica e Medicina Social e do Trabalho, Faculdade de Medicina FMUSP (FdTG), University of São Paulo, Brazil.
Maíra P M BaldassinFaculty of Medicine-University of São Paulo (GP, TA, MC, MPMB, TM, FCSS, LAMF, JC); Institute of Infectious Diseases "Emilio Ribas" (MEH, JS, ACPdO); and Departamento de Medicina Legal, Ética Médica e Medicina Social e do Trabalho, Faculdade de Medicina FMUSP (FdTG), University of São Paulo, Brazil.
Tatiane MitikoFaculty of Medicine-University of São Paulo (GP, TA, MC, MPMB, TM, FCSS, LAMF, JC); Institute of Infectious Diseases "Emilio Ribas" (MEH, JS, ACPdO); and Departamento de Medicina Legal, Ética Médica e Medicina Social e do Trabalho, Faculdade de Medicina FMUSP (FdTG), University of São Paulo, Brazil.
Flávia C Silva SalesFaculty of Medicine-University of São Paulo (GP, TA, MC, MPMB, TM, FCSS, LAMF, JC); Institute of Infectious Diseases "Emilio Ribas" (MEH, JS, ACPdO); and Departamento de Medicina Legal, Ética Médica e Medicina Social e do Trabalho, Faculdade de Medicina FMUSP (FdTG), University of São Paulo, Brazil.
Michel E HaziotFaculty of Medicine-University of São Paulo (GP, TA, MC, MPMB, TM, FCSS, LAMF, JC); Institute of Infectious Diseases "Emilio Ribas" (MEH, JS, ACPdO); and Departamento de Medicina Legal, Ética Médica e Medicina Social e do Trabalho, Faculdade de Medicina FMUSP (FdTG), University of São Paulo, Brazil.ORCID 0000-0002-3549-1992
Jerusa SmidFaculty of Medicine-University of São Paulo (GP, TA, MC, MPMB, TM, FCSS, LAMF, JC); Institute of Infectious Diseases "Emilio Ribas" (MEH, JS, ACPdO); and Departamento de Medicina Legal, Ética Médica e Medicina Social e do Trabalho, Faculdade de Medicina FMUSP (FdTG), University of São Paulo, Brazil.ORCID 0000-0001-9513-0964
Luiz A M FonsecaFaculty of Medicine-University of São Paulo (GP, TA, MC, MPMB, TM, FCSS, LAMF, JC); Institute of Infectious Diseases "Emilio Ribas" (MEH, JS, ACPdO); and Departamento de Medicina Legal, Ética Médica e Medicina Social e do Trabalho, Faculdade de Medicina FMUSP (FdTG), University of São Paulo, Brazil.
Fernanda de Toledo GonçalvesFaculty of Medicine-University of São Paulo (GP, TA, MC, MPMB, TM, FCSS, LAMF, JC); Institute of Infectious Diseases "Emilio Ribas" (MEH, JS, ACPdO); and Departamento de Medicina Legal, Ética Médica e Medicina Social e do Trabalho, Faculdade de Medicina FMUSP (FdTG), University of São Paulo, Brazil.ORCID 0000-0002-8707-7267
Augusto C Penalva de OliveiraFaculty of Medicine-University of São Paulo (GP, TA, MC, MPMB, TM, FCSS, LAMF, JC); Institute of Infectious Diseases "Emilio Ribas" (MEH, JS, ACPdO); and Departamento de Medicina Legal, Ética Médica e Medicina Social e do Trabalho, Faculdade de Medicina FMUSP (FdTG), University of São Paulo, Brazil.
Jorge CassebFaculty of Medicine-University of São Paulo (GP, TA, MC, MPMB, TM, FCSS, LAMF, JC); Institute of Infectious Diseases "Emilio Ribas" (MEH, JS, ACPdO); and Departamento de Medicina Legal, Ética Médica e Medicina Social e do Trabalho, Faculdade de Medicina FMUSP (FdTG), University of São Paulo, Brazil.ORCID 0000-0002-4553-2559
Fundação Faculdade de Medicina · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHuman T-cell lymphotropic virus type 1 (HTLV-1) infection is associated not only with some severe manifestations, such as HTLV-1-associated myelopathy (HAM) and ATLL, but also with other, less severe conditions. Some studies have reported neurologic manifestations that did not meet all the criteria for the diagnosis of HAM in individuals infected with HTLV-1; these conditions may later progress to HAM or constitute an intermediate clinical form, between asymptomatic HTLV-1 carriers and those with full myelopathy. This study evaluated the prognostic value and looked for a possible association of those parameters with the intermediate syndrome (IS) status and HAM status.

methodsProviral load (PVL), spontaneous lymphoproliferation, interferon (IFN)-γ spontaneous production was quantified in samples of asymptomatic and HAM patients, as well as patients with IS.

resultsThe critical age range was 50-60 years for IS outcome and more of 60 years for HAM outcome, with an increased risk of 2.5-fold for IS and 6.8-fold for HAM. IFN-γ was increased in patients with IS compared with asymptomatic carriers (ACs) (

conclusionIFN-γ has high specificity of prediction of subject remain asymptomatic compared with PVL and lymphoproliferation assay tests. IFN-γ has been shown to be a biomarker of progression to intermediate stage and to HAM. The association of other markers with manifestations associated with HTLV-1 infection that does not meet the HAM criteria should be verified.

Identifiers

PMID33842066
PMCPMC8032423
OpenAlexW3032067900

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.